Spondyloarthropathies: Beyond Classical RA
Spondyloarthropathies (SpA) are a group of inflammatory joint diseases distinct from RA:
- Psoriatic Arthritis (PsA): ~2% of the population, associated with ginger psoriasis, affects peripheral joints, entheses, and nails.
- Ankylosing Spondylitis (AS): axial inflammation (sacroiliac, spine), predominant enthesitis.
Central mechanism: IL-23/IL-17 axis — IL-23 differentiates Th17 → IL-17A → inflammatory cascade in joints, entheses, and bone. IL-17 is the primary therapeutic target (secukinumab, ixekizumab).
Ginger Mechanisms in SpA
| Target | Role in SpA | Ginger Effect |
|---|---|---|
| IL-23 (macrophages) | Th17 differentiation ↑ | NF-κB ↓ macrophages → IL-23 ↓ |
| IL-17A/F (Th17) | Enthesis/bone/skin inflammation | STAT3 ↓, RORγt ↓ → IL-17 ↓ |
| NF-κB enthesocytes | Enthesitis → mechanical pain | NF-κB ↓ → IL-6, MMP-3 ↓ |
| RANKL bone | Bone erosion | RANKL ↓ → osteoclasts ↓ |
| TNF-α | SpA cascade amplification | TNF-α ↓ via NF-κB |
| NF-κB keratinocytes | Cutaneous psoriasis | Reduced ginger skin comorbidity |
IL-23/IL-17 Axis Inhibition (Core of SpA)
Ginger inhibits IL-17 by reducing STAT3 (transcription factor essential for Th17 differentiation by IL-23) and RORγt (master transcription factor of Th17), and by directly reducing IL-17A, IL-17F expression in activated Th17 cells. Furthermore, ginger inhibits NF-κB in macrophages → ↓ IL-23 production → less Th17 differentiation upstream.
Enthesitis Reduction
The enthesis (tendon-bone junction) is the primary pathogenic site of SpA. IL-17 and TNF-α induce NF-κB in enthesocytes → overproduction of local cytokines and metalloproteases. Ginger inhibits NF-κB in enthesocytes → ↓ local IL-6, MMP-3 → less enthesitis → ↓ mechanical pain at entheses.
Bone Protection: RANKL and Erosions
In PsA and AS, IL-17 and TNF-α stimulate RANKL in enthesocytes and osteoblasts → osteoclasts → periarticular bone erosions. Ginger inhibits NF-κB → ↓ RANKL → ↓ entheseal osteoclasts → less bone erosions.
GIMBER and SpA: The Th17 Enhancer
- Sugar → systemic NF-κB → macrophages → IL-23 ↑ → Th17 ↑ → IL-17 ↑ → SpA exacerbated
- Fructose → AGE → RAGE → NF-κB → enhanced entheseal inflammation
- Obesity (AMPK ↓) → adipokines (leptin) → pro-inflammatory Th17
❓ FAQ — Ginger and Spondyloarthropathies
Q: Does ginger replace anti-IL-17 biologics (secukinumab) for PsA/AS?
A: No. Secukinumab is the reference biological treatment for moderate to severe SpA. Ginger shares the IL-17 ↓ mechanism but with much lower potency. It can complement treatment but never replace it. Consult a rheumatologist.
Q: Does sugar worsen psoriatic arthritis?
A: Yes — obesity (correlated with sugar consumption) is a risk factor for PsA and exacerbates activity. TNF-α and IL-17 are higher in obese PsA patients.
Related articles
Read more about related topics:
- Ginger and skin autoimmune diseases: advanced psoriasis, vitiligo and lichen planus — IL-17, Nrf2 and melanocytes — INTI
- Ginger and rheumatoid arthritis: IL-17, Th17/Treg, TNF-α and PDGF — advanced mechanisms
- ginger Crohn-colitis-ulcerosa-nf-kb-mucosaal-th17-treg-nlrp3-inti">Ginger and inflammatory bowel diseases: Crohn's, ulcerative colitis — mucosal NF-κB, Th17/Treg and NLRP3 — INTI
- Ginger and thyroid: thyroide-hashimoto-hypothyroidie">ginger Hashimoto, hypothyroidism and nodules — NF-κB, Th17/Treg and TPO — INTI
- Ginger and psoriasis: reducing plaques, IL-17/IL-23 inflammation and itching naturally
- Behçet's Disease: Systemic Vasculitis, NF-kB, IL-17 and Ginger
- Psoriasis in Belgium: sugar, IL-17, Th17 and ginger (2025)
- Ulcerative Colitis (UC) in Belgium: sugar, dysbiosis in the large intestine and ginger as support for remission